The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer

Rosa Tambaro, Giovanni Scambia, Massimo Di Maio, Carmela Pisano, Emiddio Barletta, Vincenzo Rosario Iaffaioli, Sandro Pignata

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Cervical cancer is among the major health problems world-wide although advances in screening programs. Surgery and radiotherapy are the treatment modalities of choice for early and locally advanced cervical cancer. However, the role of chemotherapy in this setting has been better investigated in the latest years. To improve loco-regional control in locally advanced disease, authors have tested both neo-adjuvant chemotherapy and concurrent chemoradiotherapy. From 1999 NCI clinical announcement, concurrent cisplatin-based chemoradiation is considered the treatment of choice for cervical cancer patients requiring radiation therapy. Neo-adjuvant chemotherapy is reaching encouraging results in IB bulky-IIA cervical cancer, but further investigation are ongoing in locally advanced cervical setting. The optimal treatment for patients with metastatic or recurrent cervical cancer is still undefined and chemotherapy is used with palliation intent. Cisplatin remains the most active cytotoxic agents, although combinations of cisplatin with paclitaxel, topotecan, vinorelbine, have shown encouraging results in phase II and in early phase III studies. This paper reviews the role of chemotherapy in the management of patients with locally advanced, metastatic and recurrent cervical cancer. Studies discussed in this paper were selected trough a search in the med-line database performed in October 2003.

Original languageEnglish
Pages (from-to)33-44
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Volume52
Issue number1
DOIs
Publication statusPublished - Oct 2004

Fingerprint

Uterine Cervical Neoplasms
Drug Therapy
Adjuvant Chemotherapy
Cisplatin
Radiotherapy
Adjuvant Chemoradiotherapy
Topotecan
Cytotoxins
Chemoradiotherapy
Therapeutics
Databases

Keywords

  • Cervical cancer
  • Chemotherapy
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. / Tambaro, Rosa; Scambia, Giovanni; Di Maio, Massimo; Pisano, Carmela; Barletta, Emiddio; Iaffaioli, Vincenzo Rosario; Pignata, Sandro.

In: Critical Reviews in Oncology/Hematology, Vol. 52, No. 1, 10.2004, p. 33-44.

Research output: Contribution to journalArticle

Tambaro, Rosa ; Scambia, Giovanni ; Di Maio, Massimo ; Pisano, Carmela ; Barletta, Emiddio ; Iaffaioli, Vincenzo Rosario ; Pignata, Sandro. / The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. In: Critical Reviews in Oncology/Hematology. 2004 ; Vol. 52, No. 1. pp. 33-44.
@article{63310fed43a4416da66437678427e2a9,
title = "The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer",
abstract = "Cervical cancer is among the major health problems world-wide although advances in screening programs. Surgery and radiotherapy are the treatment modalities of choice for early and locally advanced cervical cancer. However, the role of chemotherapy in this setting has been better investigated in the latest years. To improve loco-regional control in locally advanced disease, authors have tested both neo-adjuvant chemotherapy and concurrent chemoradiotherapy. From 1999 NCI clinical announcement, concurrent cisplatin-based chemoradiation is considered the treatment of choice for cervical cancer patients requiring radiation therapy. Neo-adjuvant chemotherapy is reaching encouraging results in IB bulky-IIA cervical cancer, but further investigation are ongoing in locally advanced cervical setting. The optimal treatment for patients with metastatic or recurrent cervical cancer is still undefined and chemotherapy is used with palliation intent. Cisplatin remains the most active cytotoxic agents, although combinations of cisplatin with paclitaxel, topotecan, vinorelbine, have shown encouraging results in phase II and in early phase III studies. This paper reviews the role of chemotherapy in the management of patients with locally advanced, metastatic and recurrent cervical cancer. Studies discussed in this paper were selected trough a search in the med-line database performed in October 2003.",
keywords = "Cervical cancer, Chemotherapy, Radiotherapy",
author = "Rosa Tambaro and Giovanni Scambia and {Di Maio}, Massimo and Carmela Pisano and Emiddio Barletta and Iaffaioli, {Vincenzo Rosario} and Sandro Pignata",
year = "2004",
month = "10",
doi = "10.1016/j.critrevonc.2004.05.003",
language = "English",
volume = "52",
pages = "33--44",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer

AU - Tambaro, Rosa

AU - Scambia, Giovanni

AU - Di Maio, Massimo

AU - Pisano, Carmela

AU - Barletta, Emiddio

AU - Iaffaioli, Vincenzo Rosario

AU - Pignata, Sandro

PY - 2004/10

Y1 - 2004/10

N2 - Cervical cancer is among the major health problems world-wide although advances in screening programs. Surgery and radiotherapy are the treatment modalities of choice for early and locally advanced cervical cancer. However, the role of chemotherapy in this setting has been better investigated in the latest years. To improve loco-regional control in locally advanced disease, authors have tested both neo-adjuvant chemotherapy and concurrent chemoradiotherapy. From 1999 NCI clinical announcement, concurrent cisplatin-based chemoradiation is considered the treatment of choice for cervical cancer patients requiring radiation therapy. Neo-adjuvant chemotherapy is reaching encouraging results in IB bulky-IIA cervical cancer, but further investigation are ongoing in locally advanced cervical setting. The optimal treatment for patients with metastatic or recurrent cervical cancer is still undefined and chemotherapy is used with palliation intent. Cisplatin remains the most active cytotoxic agents, although combinations of cisplatin with paclitaxel, topotecan, vinorelbine, have shown encouraging results in phase II and in early phase III studies. This paper reviews the role of chemotherapy in the management of patients with locally advanced, metastatic and recurrent cervical cancer. Studies discussed in this paper were selected trough a search in the med-line database performed in October 2003.

AB - Cervical cancer is among the major health problems world-wide although advances in screening programs. Surgery and radiotherapy are the treatment modalities of choice for early and locally advanced cervical cancer. However, the role of chemotherapy in this setting has been better investigated in the latest years. To improve loco-regional control in locally advanced disease, authors have tested both neo-adjuvant chemotherapy and concurrent chemoradiotherapy. From 1999 NCI clinical announcement, concurrent cisplatin-based chemoradiation is considered the treatment of choice for cervical cancer patients requiring radiation therapy. Neo-adjuvant chemotherapy is reaching encouraging results in IB bulky-IIA cervical cancer, but further investigation are ongoing in locally advanced cervical setting. The optimal treatment for patients with metastatic or recurrent cervical cancer is still undefined and chemotherapy is used with palliation intent. Cisplatin remains the most active cytotoxic agents, although combinations of cisplatin with paclitaxel, topotecan, vinorelbine, have shown encouraging results in phase II and in early phase III studies. This paper reviews the role of chemotherapy in the management of patients with locally advanced, metastatic and recurrent cervical cancer. Studies discussed in this paper were selected trough a search in the med-line database performed in October 2003.

KW - Cervical cancer

KW - Chemotherapy

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=4444331623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444331623&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2004.05.003

DO - 10.1016/j.critrevonc.2004.05.003

M3 - Article

VL - 52

SP - 33

EP - 44

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -